Gustavo de Oliveira Almeida, Thiago Faraco Nienkötter, Caroline Cristine Almeida Balieiro, Eric Pasqualotto, Júlia Braga Cintra, Henrique Champs Porfírio Carvalho, Ana Laura Soares Silva, Júlia Camargo Kabariti, Bárbara Silvestre Minucci, Edmundo Damiani Bertoli, Camila Mota Guida
BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) have emerged as an effective therapeutic class for weight loss. However, the efficacy of these agents in reducing cardiovascular endpoints among patients living with obesity or overweight is unclear. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1 RAs versus placebo in patients with obesity or overweight. We searched PubMed, Cochrane, and Embase databases...
May 11, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions